Eli Lilly & Co. — Sponsor Intelligence | 137 EU Trials

Filter these 137 trials by condition, phase, country and more.

Open in Search →

137 Registered trials

45 Recruiting

85 Completed trials

24 Countries active

122 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 77 Phase II/III: 1 Phase II: 24 Phase I/II: 2 Phase IV: 4 Phase I: 16 Phase I (Other): 11 Phase I (FiH): 1 Other: 1

Oversight events:

1 serious breach 31 temporary halts 2 unexpected events 4 corrective measures across 12 trials

View oversight register →

100%

85 of 85 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colitis ulcerative 2 Amyotrophic lateral sclerosis 1 Neurodegenerative disorder 1 Crohn´s disease 1 Crohn's disease 1 Type 2 diabetes mellitus 1

Top IMPs

MIRIKIZUMAB 11 ORFORGLIPRON HEMICALCIUM 11 TIRZEPATIDE 11 ABEMACICLIB 10 LY3437943 SODIUM 9 BARICITINIB 8 LEBRIKIZUMAB 4 LY3841136 SODIUM 4 DONANEMAB 3 FLORTAUCIPIR (18F) 3 LY3537982 3 3-((1S,2S)-1-(5-((S)-2,2-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2-((S)-3-(3-(4-FLUORO-1-METHYL-1H-INDAZOL-5-YL)-2-OXO-2,3-DIHYDRO-1H-IMIDAZOL-1-YL)-2-(4-FLUORO-3,5-DIMETHYLPHENYL)-4-METHYL-4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBONYL)-1H-INDOL-1-YL)-2-METHYLCYCLOPROPYL)-5-OXO-1,2,4-OXADIAZOL-4-IDE HEMICALCIUM 2

All trials — page 4

137 total

A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. Ended

2023-509568-81-00 Phase I 5 countries
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TR… Ended

2023-506082-60-00 Phase II 3 countries TIRZEPATIDE
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Phase III 13 countries TIRZEPATIDE
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended

2023-506771-10-00 Phase III 9 countries ABEMACICLIB
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Phase III 8 countries LY3484356
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended

2023-505835-11-00 Phase III 5 countries GALCANEZUMAB
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended

2023-505836-36-00 Phase III 4 countries GALCANEZUMAB
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juven… Ended

2023-507184-19-00 Phase III 7 countries
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations. Ended

2024-515149-41-00 Phase I 1 country
A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations Ended

2024-515150-24-00 Phase I 2 countries
EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers Ended

2023-506785-32-00 Phase I (Other) 3 countries
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Phase III 14 countries MIRIKIZUMAB
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Ended

2024-512102-25-00 Phase I (Other) 1 country (2R,4R)-1-(3-CHLORO-2-FLUOROBENZYL)-4-((3-FLUORO-6-((5-METHYL-1H-PYRAZOL-3-YL)AM…
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended

2023-506782-56-00 Phase III 9 countries CABOZANTINIB
A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended

2023-506783-14-00 Phase III 7 countries
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged … Ended

2023-507678-42-00 Phase IV 4 countries
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended

2023-506777-36-00 Phase II/III 6 countries ABEMACICLIB
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Phase III 14 countries MIRIKIZUMAB
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Phase III 16 countries ABEMACICLIB
A Study of LY3200882 in Participants With Solid Tumors. Ended

2023-507177-17-00 Phase I 1 country
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer Ended

2023-506788-32-00 1 country
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer Ended

2023-507175-22-00 Phase II 1 country ABEMACICLIB
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Ended

2023-506779-82-00 Phase III 1 country ABEMACICLIB
A Study of abemaciclib Combined with Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Ended

2023-506781-30-00 Phase III 5 countries

Showing 73–96 of 137 trials

← All sponsors A–Z